Buoyed By T-DM1 EMILIA Data, Roche Leaps To Early Breast Cancer Trial
23:21 EDT 3 Jun 2012 | Elsevier Business Intelligence
In Phase III EMILIA study, Herceptin-containing antibody drug conjugate demonstrates three-month progression-free survival benefit, trend toward overall survival and, importantly, better safety profile. Results pave way for new trials in earlier dise..
Original Article: Buoyed By T-DM1 EMILIA Data, Roche Leaps To Early Breast Cancer Trial
More From BioPortfolio on "Buoyed By T-DM1 EMILIA Data, Roche Leaps To Early Breast Cancer Trial"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
